Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in Active Psoriatic Arthritis
NCT00265096Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2005
- Primary completion
- May 2007
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of golimumab in psoriatic arthritis (PsA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: American College of Rheumatology 20 Response at 14 weeks and Change From Baseline in Total Radiographic Scores of the Hands and Feet at 24 weeks. Started Dec 2005; status: completed.
02
Drugs
golimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT00265096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265096.